CVS · CVS HEALTH Corp
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EPS non-GAAP | $5.16 | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted income attributable to CVS Health non-GAAP | $6.62B | Six Months Ended June 30, 2026 | — |
| Adjusted operating income non-GAAP | 10.31B | Six Months Ended June 30, 2026 | — |
|
|
|||
| Days claims payable | 41.7 | Three Months Ended June 30, 2026 | — |
| Medical benefit ratio | 86% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Medical membership | 26M | Three Months Ended June 30, 2026 | — |
| Medical membership (ASC) | 16.19M | June 30, 2026 | — |
| Medical membership (Insured) | 9.83M | June 30, 2026 | — |
| Medicare Prescription Drug Plan (stand-alone) | 3.87M | June 30, 2026 | — |
| Pharmacy claims processed | 937.7M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Prescription volume | 6.9% | Six Months Ended June 30, 2026 | — |
| Prescriptions filled | 908.2M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Same store sales increase: Front Store | 1.1% | Six Months Ended June 30, 2026 | — |
| Same store sales increase: Total | 2.7% | Six Months Ended June 30, 2026 | — |
| Total medical membership | 26.02M | June 30, 2026 | — |
| Cash flow from operations non-GAAP | $10.6B | Full-Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Healthcare Plans — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CVS
this stock
CVS HEALTH Corp
|
$119.95B | +19.6% | +7.8% | 24.8 | 1.5% |
|
UNH
Unitedhealth Group Inc
|
$353.59B | +19.3% | +11.8% | — | 1.7% |
|
ELV
Elevance Health, Inc.
|
$87.01B | +13.6% | +12.5% | 17.8 | 2.6% |
|
CI
Cigna Group
|
$74.37B | +1.2% | +11.2% | 11.7 | 1.8% |
|
HUM
Humana Inc
|
$45.39B | +49.1% | +10.1% | 40.3 | 3.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CVS | +1.5% | -14.2% | +24.6% | -9.1% | +19.6% |
| SPY | -0.4% | +2.6% | +10.7% | +2.7% | +12.5% |
| vs SPY | +1.9% | -16.8% | +13.9% | -11.9% | +7.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.